Question 1

Has Avigayil Rapp received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $1,824,153 in general payments to Avigayil Rapp across 617 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Avigayil Rapp did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Avigayil Rapp come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	567	$1,770,966
Boehringer Ingelheim International GmbH	37	$33,276
Amgen	2	$16,694
E.r. Squibb & Sons, L.L.C.	1	$1,826
Merck	8	$1,275
F. Hoffmann-la Roche AG	1	$80
Boehringer Ingelheim	1	$35

Avigayil Rapp

Payments from drug & device makers

Who reported the general payments

How this compares

Other internal medicine in Inwood